Frequent non-cardiac comorbidities in patients with chronic heart failure

被引:79
作者
Dahlström, U [1 ]
机构
[1] Linkoping Univ Hosp, Dept Cardiol, S-58185 Linkoping, Sweden
关键词
heart failure; non-cardiac comorbidities; prognosis;
D O I
10.1016/j.ejheart.2005.01.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart failure (HF) in elderly patients is associated with more diffuse symptoms and signs due to the presence of other noncardiac comorbidities. This can cause difficulties in assessing the correct diagnosis and initiating appropriate therapy. The four most frequently occurring noncardiac comorbidities and therapies used to treat them are discussed in the present paper. Hypertension is an important precursor of HF, and is still the most common risk factor for HF in the general population. About 50% of patients with untreated hypertension will develop HE Pressure overload leads to the development of left ventricular hypertrophy (LVH) and diastolic dysfunction. Diabetes, which occurs in about 20-30% of patients with HF, is an important comorbidity resulting in morphological and metabolic disturbances affecting myocardial blood flow and hormonal regulation leading to a poor outcome and necessitating aggressive conventional treatment. Chronic obstructive pulmonary disease (COPD), occurs in approximately 20-30% of heart failure patients, and may complicate HF treatment, it is therefore important to recognize and treat it effectively. Finally, the early detection of anemia, which occurs in 20-30% of HF patients, is important since it is associated with functional impairment and increased mortality and morbidity. Combined treatment with erythropoietin and intravenous iron has shown beneficial effects on clinical symptoms and morbidity. In conclusion early detection of concomitant diseases in patients with HF is important and should be considered carefully when initiating therapy. (C) 2005 European Society of Cardiology. Published by Elsevier B.V All rights reserved.
引用
收藏
页码:309 / 316
页数:8
相关论文
共 76 条
[1]  
ANAND IS, 1993, BRIT HEART J, V70, P357
[2]   QUANTITATIVE STRUCTURAL-ANALYSIS OF THE MYOCARDIUM DURING PHYSIOLOGICAL GROWTH AND INDUCED CARDIAC-HYPERTROPHY - A REVIEW [J].
ANVERSA, P ;
RICCI, R ;
OLIVETTI, G .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 7 (05) :1140-1149
[3]   How hyperglycemia promotes atherosclerosis: molecular mechanisms [J].
Aronson, Doron ;
Rayfield, Elliot J. .
CARDIOVASCULAR DIABETOLOGY, 2002, 1 (1)
[4]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[5]   Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure [J].
Braunstein, JB ;
Anderson, GF ;
Gerstenblith, G ;
Weller, W ;
Niefeld, M ;
Herbert, R ;
Wu, AW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (07) :1226-1233
[7]   Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995 [J].
Brown, AM ;
Cleland, JGF .
EUROPEAN HEART JOURNAL, 1998, 19 (07) :1063-1069
[8]  
BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315
[9]   A COMPARISON OF ENALAPRIL WITH HYDRALAZINE ISOSORBIDE DINITRATE IN THE TREATMENT OF CHRONIC CONGESTIVE-HEART-FAILURE [J].
COHN, JN ;
JOHNSON, G ;
ZIESCHE, S ;
COBB, F ;
FRANCIS, G ;
TRISTANI, F ;
SMITH, R ;
DUNKMAN, WB ;
LOEB, H ;
WONG, ML ;
BHAT, G ;
GOLDMAN, S ;
FLETCHER, RD ;
DOHERTY, J ;
HUGHES, CV ;
CARSON, P ;
CINTRON, G ;
SHABETAI, R ;
HAAKENSON, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (05) :303-310
[10]  
*COPERNICUS STUD G, 1907, NEW ENGL J MED, V344, P1651